Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR

Rajneesh Nath, MD, Zheng Zhou, MD PhD, Jan Cerny, MD PhD, Hai-Lin Wang, MPH, Khalid Bo-Subait, Zartash Guth, Gulrayz Ahmed, Muhammad Wagas Khan, Gerhard Carl Hildebrandt, MD, Hassan B. Alkhateeb, MD, Moussab Damlaj, MD, Mrinal M. Patnaik, MD MBBS, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD, Marcos de Lima, MD, Mark R. Litzow, MD, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 3456.

https://doi.org/10.1182/blood-2018-99-116795

Published: 2018

Journal Articles

High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia

Neeraj Y Saini, MD, Jan Cerny, MD PhD, Vanessa Furtado, MD, Angela Desmond, Zheng Zhou, Glen D. Raffel, MD, Imran Puthawala, Jayde Bednarik, PharmD, Lindsey Shanahan, Patricia Minehart Miron, PhD, Bruce Woda, MD, Muthalagu Ramanathan, MD, Rajneesh Nath, MD

Blood (2018) 132 (Supplement 1): 1430.

https://doi.org/10.1182/blood-2018-99-116857

Published: 2018

Journal Articles

Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin

Blood (2017) 130 (Supplement 1): 4141.

https://doi.org/10.1182/blood.V130.Suppl_1.4141.4141

Published: 2017

Journal Articles

Outcomes of Allogeneic Stem Cell Transplant (Allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in Patients Older Than 75 Years: A Single Center Analysis

Rajneesh Nath, MD, Jan Cerny, MD PhD, Muthalagu Ramanathan, MD, Zheng Zhou, MD PhD, Neng Yu, MD, Glen D Raffel, MD PhD, Jayde Bednarik, PharmD

Blood (2016) 128 (22): 5875.

https://doi.org/10.1182/blood.V128.22.5875.5875

Published: 2016

Journal Articles

Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies

Blood (2016) 128 (22): 103.

https://doi.org/10.1182/blood.V128.22.103.103

Published: 2016

Journal Articles

Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features

Blood (2016) 128 (22): 513.

https://doi.org/10.1182/blood.V128.22.513.513

Published: 2016

Journal Articles

Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine

Rachel Gerstein, PhD, Zheng Zhou, MD PhD, Hong Zhang, PhD, Andrew Evens, DO, MSc, FACP, Nicole Walsh, PhD, Leonard Shultz, Rita Bortell, PhD, Michael Brehm, PhD, Jan Cerny, MD PhD, Giles Whalen, MD, Jack Leonard, PhD, Bruce Woda, MD, Dale Greiner, PhD, Alan G. Rosmarin, MD

Blood (2015) 126 (23): 5408.

https://doi.org/10.1182/blood.V126.23.5408.5408

Published: 2015

Journal Articles

Prevalence,Type, and Risk Factors for Bleeding in a Large Cohort of Myeloproliferative Neoplasm Patients

Elizabeth M Kander, MD, Sania S. Raza, MD, Zheng Zhou, MD PhD, David Dittmann, Juehua Gao, MD, PhD, Brandon McMahon, MD, Brady L Stein, MDMHS

Blood (2014) 124 (21): 3207.

https://doi.org/10.1182/blood.V124.21.3207.3207

Published: 2014

Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2014) 124 (21): 3046.

https://doi.org/10.1182/blood.V124.21.3046.3046

Published: 2014

Journal Articles

Diagnosis and Management of Polycythemia Vera in the Post- JAK2 V617F Discovery Era: A Survey of Practice Patterns

Brady L Stein, MDMHS, Elizabeth M Kander, MD, Zheng Zhou, MD PhD, Michael B. Streiff, MD, Alison R Moliterno, MD, Jerry L. Spivak, MD

Blood (2014) 124 (21): 2172.

https://doi.org/10.1182/blood.V124.21.2172.2172

Published: 2014

Journal Articles

Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG)

Rajneesh Nath, MD, Muthalagu Ramanathan, MD, Jan Cerny, MD PhD, Zheng Zhou, MD PhD, Glen D Raffel, MD PhD, Jayde Bednarik, Pharm D, Neng Yu, MD, Laura J Petrillo-Deluca, PA-C, Zeina Al-Mansour, MD, Zankar Desai

Blood (2014) 124 (21): 1152.

https://doi.org/10.1182/blood.V124.21.1152.1152

Published: 2014

Journal Articles

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael Millenson, Joyce Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter

Blood (2014) 123 (6): 837–842.

https://doi.org/10.1182/blood-2013-09-524108

Published: 2014

Includes: Supplemental data

Journal Articles

Clinical Factors Associated With Bleeding In Ph-Negaitve MPN

Sania S. Raza, MD, Zheng Zhou, MD, PhD, Brady L. Stein, MD

Blood (2013) 122 (21): 3605.

https://doi.org/10.1182/blood.V122.21.3605.3605

Published: 2013

Journal Articles

The Natural History Of Polycythemia Vera In Two Diagnostic Eras

Brady L Stein, MD MHS, Zheng Zhou, MD, PhD, Jerry L. Spivak, MD, Alison R. Moliterno, MD

Blood (2013) 122 (21): 4078.

https://doi.org/10.1182/blood.V122.21.4078.4078

Published: 2013

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Idarubicin Appears Equivalent to Dose-Intense daunorubicin for AML Induction

Steven Trifilio, Zheng Zhou, Jayesh Mehta, MD, Colleen Czerniak, Judy Pi, Molly Koslosky, Deborah Greenberg, Mihaela Pantiru, MD, Jessica Altman

Blood (2012) 120 (21): 3581.

https://doi.org/10.1182/blood.V120.21.3581.3581

Published: 2012

Journal Articles

Dose-Intense Etoposide and Cyclophosphamide without Stem Cell Transplantation for the Treatment of Primary Refractory and Relapsed Acute Myeloid Leukemia

Steven Trifilio, Zheng Zhou, Jessica K. Altman, MD, Mihaela Pantiru, MD, Jayesh Mehta, MD

Blood (2012) 120 (21): 4314.

https://doi.org/10.1182/blood.V120.21.4314.4314

Published: 2012

Journal Articles

Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1 st Complete Remission (CR): A Single Institution Experience

Amanpreet Buttar, MD, Deepa Jagadeesh, MD, MPH, Jan Cerny, MD, PhD, Muthalagu Ramanathan, MD, Zheng Zhou, MD, PhD, Laura Petrillo-Deluca, PAC, Natasha Tarrasky, PAC, Jayde Bednarik, Pharm D, Zankar Desai, William V Walsh, MD, Rajneesh Nath, MD

Blood (2011) 118 (21): 4505.

https://doi.org/10.1182/blood.V118.21.4505.4505

Published: 2011

Journal Articles

High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML)

Muthalagu Ramanathan, MD, Zheng Zhou, MD, Jan Cerny, MD, PhD, Glen D Raffel, M.D, Ph.D., Laura Petrillo-Deluca, William Vincent Walsh, MD, Venu Bathini, MD, Micheal Vail, Karen Smethers, Bruce Woda, MD, Patricia Miron, MD, Alan G. Rosmarin, MD, Rajneesh Nath, MD

Blood (2010) 116 (21): 3290.

https://doi.org/10.1182/blood.V116.21.3290.3290

Published: 2010

Journal Articles

Neogenin inhibits HJV secretion and regulates BMP-induced hepcidin expression and iron homeostasis

Dae-Hoon Lee, Li-Juan Zhou, Zheng Zhou, Jian-Xin Xie, Ji-Ung Jung, Yu Liu, Cai-Xia Xi, Lin Mei, Wen-Cheng Xiong

Blood (2010) 115 (15): 3136–3145.

https://doi.org/10.1182/blood-2009-11-251199

Published: 2010

Includes: Supplemental data

NARROW

Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR

High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia

Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin

Outcomes of Allogeneic Stem Cell Transplant (Allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in Patients Older Than 75 Years: A Single Center Analysis

Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies

Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features

Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine

Prevalence,Type, and Risk Factors for Bleeding in a Large Cohort of Myeloproliferative Neoplasm Patients

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Diagnosis and Management of Polycythemia Vera in the Post- JAK2 V617F Discovery Era: A Survey of Practice Patterns

Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG)

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Clinical Factors Associated With Bleeding In Ph-Negaitve MPN

The Natural History Of Polycythemia Vera In Two Diagnostic Eras

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Idarubicin Appears Equivalent to Dose-Intense daunorubicin for AML Induction

Dose-Intense Etoposide and Cyclophosphamide without Stem Cell Transplantation for the Treatment of Primary Refractory and Relapsed Acute Myeloid Leukemia

Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1 st Complete Remission (CR): A Single Institution Experience

High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML)

Neogenin inhibits HJV secretion and regulates BMP-induced hepcidin expression and iron homeostasis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only